23:59 , Jan 10, 2017 |  BC Extra  |  Clinical News

Paper suggests Aravive compound could block Zika

In a study published Tuesday in Cell Reports, researchers from INSERM and Aravive Biologics Inc. (Houston, Texas) said Aravive’s preclinical candidate Aravive-S6 could protect glial cells from Zika infection. Aravive-S6 is an Fc-fusion protein that blocks...
19:41 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); breast cancer; ovarian cancer Cell culture and mouse studies suggest a GAS6-binding AXL decoy could help treat AML and metastatic breast and ovarian cancers. The AXL decoy, Aravive-S6, consisted of a...
20:46 , Dec 15, 2016 |  BC Innovations  |  Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...